BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-11-14 06:00 |
BerGenBio Reports Third Quarter 2023 Financial Results
|
English | 1.9 MB | ||
| 2023-11-14 06:00 |
BerGenBio Reports Third Quarter 2023 Financial Results
|
English | 13.7 KB | ||
| 2023-11-13 18:46 |
Financial calendar
|
English | 720 bytes | ||
| 2023-11-06 11:00 |
BerGenBio ASA: Invitation to third quarter 2023 results webcast
|
English | 142.3 KB | ||
| 2023-11-06 11:00 |
BerGenBio ASA: Invitation to third quarter 2023 results webcast
|
English | 3.5 KB | ||
| 2023-11-06 06:00 |
BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC
|
English | 132.7 KB | ||
| 2023-11-06 06:00 |
BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC
|
English | 4.4 KB | ||
| 2023-11-02 13:00 |
BerGenBio Announces Poster Presentation at Upcoming ASH Meeting
|
English | 140.6 KB | ||
| 2023-11-02 13:00 |
BerGenBio Announces Poster Presentation at Upcoming ASH Meeting
|
English | 3.6 KB | ||
| 2023-10-31 13:00 |
BerGenBio Announces Poster Presentation at Upcoming SITC Meeting
|
English | 104.2 KB | ||
| 2023-10-31 13:00 |
BerGenBio Announces Poster Presentation at Upcoming SITC Meeting
|
English | 3.8 KB | ||
| 2023-10-23 05:30 |
New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2…
|
English | 112.9 KB | ||
| 2023-10-23 05:30 |
New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2…
|
English | 4.1 KB | ||
| 2023-10-16 05:00 |
Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presen…
|
English | 144.5 KB | ||
| 2023-10-16 05:00 |
Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presen…
|
English | 4.4 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
